KER050-MD-201 : A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Principal Investigator

Mikkael Sekeres

Enrollment Status

Open

Clinical Trial ID

Institutional Protocol # 20230058

Clinical Trial Summary

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Phase

Phase II

Funding Agency/Sponsor

Industrial

Disease

Leukemia/heme

Contact Information

Phone Number +1 (305) 2434624